[Pulmonary fibrosis due to bleomycin].
Being little myelotoxic, Bleomycin (BLM) is more and more used in association with other anti-neoplastic drugs; its pulmonary toxicity is not to be overlooked and here is a recall of the risks of pulmonary fibrosis during treatment by BLM. This review is based on a personal experience of 45 cases, of which 6 were cases of respiratory insufficiency. It derived also from a study of the literature which expressed the frequency of respiratory accidents in figures varying from 2 to 94% according to the criteria of tolerance used by the authors. BLM toxicity for the pulmonary tract being important some precautions should be taken in its use: specially supervising aged patients or those with a pastpathological respiratory story; it should particularly concern the functional side, using CO ductance to trace the first signs of toxicity A total dose of 450 mg should not be exceeded.
D000368:Aged; D001761:Bleomycin / Q000009:adverse effects* / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000188:drug therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D001761:Bleomycin
Les fibroses pulmonaires à la bléomycine.